Please login to the form below

Not currently logged in

FDA insists on GnRH agonists risk warning

The FDA has issued a notification to manufacturers of a class of prostate cancer drug stating that new safety information must be added to labels

The US Food and Drug Administration (FDA) has issued a notification to manufacturers of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs used in the treatment of men with prostate cancer, informing them that they must add new safety information to the Warnings and Precautions section of drug labels.

The warning relates to the increased risk of diabetes and some cardiovascular diseases (heart attack, sudden cardiac death and stroke) in men receiving GnRH agonists for the treatment of prostate cancer.

The notification from the FDA follows an ongoing safety review issued by the authority in May 2010, which was based on the review of several published studies. 

GnRH agonists work by suppressing the production of testosterone, which is a key hormone involved in the growth of prostate cancer. This type of treatment is called androgen deprivation therapy (ADT) and has been shown to shrink or slow the growth of prostate cancer.

In the US, GnRH agonists are approved for the treatment of symptoms (palliative treatment) of advanced prostate cancer. They are sold as Lupron (manufactured by Abbott), Zoladex (AstraZeneca), Trelstar (Watson), Viadur (Alza), and Eligard (sanofi-aventis) as well as under several generic labels.

Prostate cancer is the second most common type of cancer among men in the US, after skin cancer, and usually occurs in older men. According to the Centers for Disease Control, National Center for Health Statistics and the National Cancer Institute an estimated 217,730 new cases of prostate cancer will be diagnosed in 2010. Of these, around 32,050 men will die from the disease.

21st October 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...